Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma
Nicole E. Gross, Zhehao Zhang, Jacob T. Mitchell, Soren Charmsaz, Alexei G. Hernandez, Erin M. Coyne, Sarah M. Shin, Diana Carolina Vargas Carvajal, Dimitrios N. Sidiropoulos, Yeonju Cho, Guanglan Mo, Xuan Yuan, Courtney Cannon, Jayalaxmi Suresh Babu, Melissa R. Lyman, Todd Armstrong, Luciane T. Kagohara, Katherine M. Bever, Dung T. Le, Elizabeth M. Jaffee, Elana J. Fertig, Won Jin Ho
Nicole E. Gross, Zhehao Zhang, Jacob T. Mitchell, Soren Charmsaz, Alexei G. Hernandez, Erin M. Coyne, Sarah M. Shin, Diana Carolina Vargas Carvajal, Dimitrios N. Sidiropoulos, Yeonju Cho, Guanglan Mo, Xuan Yuan, Courtney Cannon, Jayalaxmi Suresh Babu, Melissa R. Lyman, Todd Armstrong, Luciane T. Kagohara, Katherine M. Bever, Dung T. Le, Elizabeth M. Jaffee, Elana J. Fertig, Won Jin Ho
View: Text | PDF
Research Article Immunology Oncology

Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma

  • Text
  • PDF
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is highly lethal and resistant to immunotherapy. Although immune recognition can be enhanced with immunomodulatory agents including checkpoint inhibitors and vaccines, few patients experience clinical efficacy because the tumor immune microenvironment (TiME) is dominated by immunosuppressive myeloid cells that impose T cell inhibition. Inhibition of phosphodiesterase-5 (PDE5) was reported to downregulate metabolic regulators arginase and inducible NOS in immunosuppressive myeloid cells and enhance immunity against immune-sensitive tumors, including head and neck cancers. We show for the first time to our knowledge that combining a PDE5 inhibitor, tadalafil, with a mesothelin-specific vaccine, anti–programmed cell death protein 1, and anti–cytotoxic T lymphocyte–associated protein 4 yields antitumor efficacy even against immune-resistant PDAC. To determine immunologic advantages conferred by tadalafil, we profiled the TiME using mass cytometry and single-cell RNA-sequencing analysis with Domino to infer intercellular signaling. Our analyses demonstrated that tadalafil reprograms myeloid cells to be less immunosuppressive. Moreover, tadalafil synergized with the vaccine, enhancing T cell activation including mesothelin-specific T cells. Tadalafil treatment was also associated with myeloid/T cell signaling axes important for antitumor responses (e.g., Cxcr3, Il12). Our study shows that PDE5 inhibition combined with vaccine-based immunotherapy promotes pro-inflammatory states of myeloid cells, activation of T cells, and enhanced myeloid/T cell crosstalk to yield antitumor efficacy against immune-resistant PDAC.

Authors

Nicole E. Gross, Zhehao Zhang, Jacob T. Mitchell, Soren Charmsaz, Alexei G. Hernandez, Erin M. Coyne, Sarah M. Shin, Diana Carolina Vargas Carvajal, Dimitrios N. Sidiropoulos, Yeonju Cho, Guanglan Mo, Xuan Yuan, Courtney Cannon, Jayalaxmi Suresh Babu, Melissa R. Lyman, Todd Armstrong, Luciane T. Kagohara, Katherine M. Bever, Dung T. Le, Elizabeth M. Jaffee, Elana J. Fertig, Won Jin Ho

×

Figure 1

The addition of tadalafil to ICIs and mesothelin expressing listeria vaccine diminishes tumor growth.

Options: View larger image (or click on image) Download as PowerPoint
The addition of tadalafil to ICIs and mesothelin expressing listeria vac...
(A) Mice were injected with KPCY 6419c5 cells subcutaneously in the right hind limb on day 0, then vaccinated with mesothelin expressing listeria vaccine or control vaccine on day 3. Mice were treated intravenously with tadalafil or PBS 3 times per week and intraperitoneally with anti–PD-1 and anti–CTLA-4 or respective isotypes 2 times per week until day 26. (B) Tumor volumes (mm3) were measured 3 times per week starting on day 10 and plotted over time for each treatment group. Plot is representative of 2 independent runs. Mean ± SEM (n = 20, except for group 6 with n = 15). *P ≤ 0.05, **P ≤ 0.001, ****P ≤ 0.0001 by nonlinear regression. (C–H) Tumor volumes plotted individually by treatment group.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts